A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer

Trial Profile

A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Durvalumab (Primary) ; MEDI 0457 (Primary)
  • Indications Head and neck cancer; Human papillomavirus infections; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 19 May 2017 Status changed from planning to not yet recruiting.
    • 10 May 2017 Enrollment in this trial is expected to begin in the second quarter of 2017, according to an Inovio Pharmaceuticals media release.
    • 21 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top